Qualigen Therapeutics, Inc.

NasdaqCM QLGN

Qualigen Therapeutics, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2024

Qualigen Therapeutics, Inc. Free Cash Flow is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Qualigen Therapeutics, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -7.11 M, a 49.23% change year over year.
Qualigen Therapeutics, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -14.01 M, a 9.41% change year over year.
Qualigen Therapeutics, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -15.47 M, a 100.00% change year over year.
Qualigen Therapeutics, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -14.52 T, a -234,713,071.05% change year over year.

Key data

Date	Free Cash Flow	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities

NasdaqCM: QLGN

Qualigen Therapeutics, Inc.

CEO	Mr. Kevin A. Richardson II
IPO Date	June 23, 2015
Location	United States
Headquarters	2042 Corte Del Nogal
Employees	4
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.

Key trends

Past 5 years